フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Journalists and other readers should disregard the news release, THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK STUDIES OF NOXAFIL IN THE...
ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/26505/consumer.htm...
CHICAGO, Nov. 10 /PRNewswire-FirstCall/ -- Speaking at a Cardiovascular Summit of more than 150 cardiovascular experts here in advance of the...
Clinical data demonstrated continued efficacy and tolerability of LEVITRA in men with ED and high blood pressure, diabetes and/or dyslipidemia...
BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that...
KENILWORTH, N.J., Oct. 24 /PRNewswire-FirstCall/ -- More than 50 data presentations involving Schering-Plough's hepatitis products, including...
First 24-Week Results with a CCR5 Receptor Antagonist Reported TORONTO, Aug. 17 /PRNewswire-FirstCall/ -- Schering-Plough today reported that...
Greater LDL Cholesterol Reduction with VYTORIN Compared to Crestor Resulted in Greater LDL Cholesterol Goal Attainment ROME, June 19...
'Check Men's Facts' Campaign Urges Men to See their Doctor about the Connection KENILWORTH, N.J., and PHILADELPHIA, June 9...
KENILWORTH, N.J., May 23 /PRNewswire-FirstCall/ -- Schering-Plough today announced the initiation of a large multicenter clinical trial in the...
Easy-to-Use Product Combines Freezing Technology and Fast-Acting Liquid Wart Remover; First and Only FDA-Cleared OTC Treatment of its Kind...
KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced the launch of a long-term plan to identify and...
KENILWORTH, N.J., May 18 /PRNewswire-FirstCall/ -- Eight oral presentations and 23 poster presentations highlighting clinical data for...
KENILWORTH, N.J., April 19 /PRNewswire-FirstCall/ -- Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約